

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. rationale, method of making available)
2012-13							
Methylaltraxone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)	31/03/2013	Methylaltraxone – unable to recommend NHS use for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care because no evidence submission was received from the manufacturer.	x		10/04/2013	0	TA277- not recommended. Not used in the trust.
Cystic fibrosis (pseudomonas lung infection)- colistimethate sodium and tobramycin (TA276)	31/03/2013	Tobramycin and colistimethate sodium dry powders for inhalation – recommended as possible treatments for chronic pseudomonas lung infection in some people with cystic fibrosis, only as part of agreed patient access schemes. NB At time of publication, implementation guidance applies only to tobramycin as colistimethate is not available.		x	10/04/2013	10	Hospital only through Specialist Centre.
Macular oedema (diabetic) - ranibizumab (TA274). Review of TA 237	28/02/2013	Ranibizumab – possible treatment for problems with sight due to diabetic macular oedema if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment, only as part of an agreed patient access scheme.	x		29/05/2013	90	Patient pathway between MKHFT & Stoke Mandeville Hospital to be agreed.
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)	28/02/2013	Apixaban – recommended as an option for prevention of stroke and systemic embolism in people with atrial fibrillation and one or more risk factors, but without underlying heart valve disease.	x		10/04/2013	41	Use in line with policy on NOACs.
Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271)	31/01/2013	Fluocinolone acetonide implant – Not recommended when other treatments have not worked well enough.	x		10/04/2013	0	TA271- not recommended. Not used in the trust.
Urothelial tract carcinoma (transitional cell, adenocarcinoma or metastatic), adjuvant (TA272)	31/01/2013	Vinorelbine – Not recommended for this cancer if treated previously with platinum-containing drugs.	x		10/04/2013	0	TA272- not recommended. Not used in the trust.
Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)	31/01/2013	Tadalafil – unable to recommend NHS use because no evidence received from manufacturer.	x		10/04/2013	0	TA273- not recommended. Not used in the trust.
Melanoma (BRAF V600 mutation positive, unresectable or metastatic) - vemurafenib (TA269)	31/12/2012	Vemurafenib – recommended for this indication only as part of agreed patient access scheme.		x	29/05/2013	149	Noted for formulary inclusion. Not stocked in pharmacy and not used in the trust.
Leukemia (acute myeloid) - decitabine (terminated appraisal) (TA270)	31/12/2012	Decitabine – unable to make recommendation about NHS use due to lack of evidence submission.	x		10/04/2013	0	TA270- not recommended. Not used in the trust. TA position noted in relation to the CDF.
Melanoma (stage III or IV) - ipilimumab (TA268)	31/12/2012	Ipilimumab – recommended option after prior therapy for advanced melanoma (unresectable or metastatic), only as part of agreed patient access scheme.	x		31/03/2013	90	Noted for formulary inclusion. Not stocked in pharmacy.
Chronic heart failure - ivabradine (TA267)	30/11/2012	Ivabradine – recommended option for stable chronic heart failure after 4 weeks of optimised standard drugs alone if heart function meets stated parameters. Given with standard drugs, or instead of beta blockers if not tolerated.	x		28/02/2013	0	Drug already on formulary. Cardiologists have confirmed use in line with NICE guidance.
Cystic fibrosis - mannitol dry powder for inhalation (TA266)	30/11/2012	Mannitol dry powder for inhalation – recommended option for cystic fibrosis if rDNase or other osmotic drugs are inappropriate, and lung function is rapidly declining.	x				
Bone metastases from solid tumours - denosumab (TA265)	31/10/2012	Denosumab – a recommended option instead of a bisphosphonate for preventing skeletal-related events caused by bone metastases from solid tumours. Not recommended for bone metastases from prostate cancer.	x		20/11/2012	20	Noted for formulary inclusion. Not stocked in pharmacy.
Stroke (acute, ischaemic) - alteplase (TA264)	25/09/2012	Alteplase – a recommended option within 4.5 hours of an acute ischaemic stroke if imaging shows no haemorrhage.		x	20/11/2012	56	
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)	22/08/2012	Bevacizumab with Capecitabine – not recommended when other chemotherapy (inc. taxanes, anthracyclines) is not appropriate, or if taxanes or anthracyclines given in past 12mths.	x		18/09/2012	0	Available to MK patients but issued at Northampton General Hospital
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261)	23/07/2012	Rivaroxaban – a recommended option for treating DVT, and to help prevent a pulmonary embolism or another DVT.	x		21/08/2012	29	Available as an option. Dabigatran used as per clinician choice an experience.
Ulcerative colitis (moderate to severe, second line) - adalimumab (TA262)	26/07/2012	Adalimumab – unable to recommend NHS use. TA terminated due to lack of evidence submission.	x		22/08/2012	0	TA262- not recommended
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257)	04/07/2012	Lapatinib & trastuzumab – not recommended with an aromatase inhibitor for post-menopausal women with HER2 and hormone receptor positive metastatic breast cancer.	x		04/07/2012	0	Available to MK patients but issued at Northampton General Hospital
Migraine (chronic) - botulinum toxin type A (TA260)	26/06/2012	Botulinum toxin – a recommended option for preventing headaches in some adults with chronic migraine.	x		17/07/2012	21	PbR excluded medicine
Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy) (TA259)	20/06/2012	Abiraterone – a recommended option for metastatic prostate cancer after testosterone reduction therapy and docetaxel.	x		20/06/2012	0	Available to MK patients but issued at Northampton General Hospital
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258)	15/06/2012	Erlotinib – a recommended first-line option in locally advanced or metastatic non-small-cell lung cancer.	x		15/06/2012	0	Available to MK patients but issued at Northampton General Hospital
Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)	24/05/2012	Rivaroxaban – a recommended option for atrial fibrillation patients with risk factors.	x		19/06/2012	26	Shared care guideline produced. Available second line to patients intolerant to warfarin or with unstable
Prostate cancer - cabazitaxel (TA255)	15/05/2012	Cabazitaxel – not recommended for patients with hormone refractory, metastatic prostate cancer who have had docetaxel.	x		19/06/2012	0	Available to MK patients but issued at Northampton General Hospital
Hepatitis C (genotype 1) - telaprevir (TA252)	14/05/2012	Telaprevir – recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous interferon treatments.	x		19/06/2012	36	Noted for formulary inclusion. Available to order when required. Not stocked in pharmacy.
Hepatitis C (genotype 1) - boceprevir (TA253)	14/05/2012	Boceprevir – recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous treatment.	x		19/06/2012	36	Noted for formulary inclusion. Available to order when required. Not stocked in pharmacy.
Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)	27/04/2012	Fingolimod – recommended for patients not responding sufficiently to beta interferon.		x	19/06/2012	53	Regional MS service based at Oxford.
Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib (TA251)	24/04/2012	For first-line treatment of chronic phase Philadelphia-chromosome-positive CML: Imatinib – recommended as an option. Nilotinib – recommended as an option only under a patient access scheme.	x		19/06/2012	56	Use in line with Thames Valley Cancer Network guidelines
Breast cancer (advanced) - eribulin (TA250)	15/04/2012	Eribulin – not recommended if cancer progressed despite two or more chemotherapy regimens.	x		19/06/2012	0	TA250- not recommended
			25	3			
			% "Yes"	% "N/A"	–	Average implement time (days)	
Adherence statistics for 2012-13			89%	11%		26	